The different sialic acid (serogroups B, C, Y, and W-135) and nonsialic acid (serogroup A) capsular polysaccharides expressed by Neisseria meningitidis are major virulence factors and are used as epidemiologic markers and vaccine targets. However, the identification of meningococcal isolates with similar genetic markers but expressing different capsular polysaccharides suggests that meningococcal clones can switch the type of capsule they express. We identified, except for capsule, isogenic serogroups B [(alpha2-->8)-linked polysialic acid] and C [(alpha2-->9)-linked polysialic acid] meningococcal isolates from an outbreak of meningococcal disease in the U. S. Pacific Northwest. We used these isolates and prototype serogroup A, B, C, Y, and W-135 strains to define the capsular biosynthetic and transport operons of the major meningococcal serogroups and to show that switching from the B to C capsule in the outbreak strain was the result of allelic exchange of the polysialyltransferase. Capsule switching was probably the result of transformation and horizontal DNA exchange in vivo of a serogroup C capsule biosynthetic operon. These findings indicate that closely related virulent meningococcal clones may not be recognized by traditional serogroup-based surveillance and can escape vaccine-induced or natural protective immunity by capsule switching. Capsule switching may be an important virulence mechanism of meningococci and other encapsulated bacterial pathogens. As vaccine development progresses and broader immunization with capsular polysaccharide conjugate vaccines becomes a reality, the ability to switch capsular types may have important implications for the impact of these vaccines.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC19312 | PMC |
http://dx.doi.org/10.1073/pnas.94.1.271 | DOI Listing |
J Sep Sci
January 2025
Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang, China.
A novel dual-wavelength ultrahigh performance liquid chromatography (UHPLC) fingerprint was established, 56 common peaks were confirmed and attributed to the source of the medicinal materials, and 13 chromatographic peaks of them were identified by UHPLC quadrupole time-of-flight (Q-TOF)-MS/MS and UHPLC-UV method. Furthermore, a simple and sensitive HPLC-quadrupole trap (Q-TRAP)-MS/MS was developed for the simultaneous determination of 16 active components with electrospray ionization (ESI) source switching between positive and negative modes in a single run. The above two methods were successfully applied for the quality evaluation of Guanxinjing capsule (GXJC).
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
B Surgery Department, Charles Nicolle Hospital, Tunis, Tunisia.
Medicine (Baltimore)
November 2024
Department of Endocrinology, Lishui Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang Province, China.
Carbohydr Polym
January 2025
School of Chemistry and Chemical Engineering, Guangxi Key Laboratory of Petrochemical Resource Processing and Process Intensification Technology, Guangxi University, Nanning 530004, China; State Key Laboratory Breeding Base of Green-Chemical Synthesis Technology, Institute of Green Petroleum Processing and Light Hydrocarbon Conversion, College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, China.
Polysaccharides-based smart fertilizers are essential for promoting plant growth, yet significant challenges exist in achieving stable structures and synchronizing nutrient release and plant growth. This study developed a temperature-responsive gating chitosan-based microcapsule (CTSMC-g-PNIPAM) by grafting N-isopropyl acrylamide (NIPAM) onto chitosan microcapsules (CTSMC) via atom transfer radical polymerization (ATRP). The interfacial crosslinking of chitosan (CTS) and terephthalendehyde (TPA) formed the CTSMC matrix with a hollow chamber structure and ensured stability.
View Article and Find Full Text PDFChemotherapy
November 2024
Department of Neurosurgery/Neuro-Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Introduction: We report the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of a multi-kinase inhibitor (TG02 capsule) as a new therapy for patients with recurrent high-grade gliomas in China.
Methods: This is a single-center, dose-escalation, open-label phase I study, which enrolled patients with recurrent high-grade gliomas who failed to temozolomide. Patients were assigned sequentially into different dose groups and received TG02 every 4 weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!